Published in Intensive Care Med on September 01, 1999
Stress induced changes in lymphocyte subpopulations and associated cytokines during whole body hyperthermia of 41.8-42.2 degrees C. Eur J Appl Physiol (2005) 0.81
Physiologic response to a simplified venovenous perfusion-induced systemic hyperthermia system. ASAIO J (2012) 0.81
Resolution of pulmonary hypertension complication during venovenous perfusion-induced systemic hyperthermia application. ASAIO J (2013) 0.77
Hyperthermia: How Can It Be Used? Oman Med J (2016) 0.76
Whole body hyperthermia: simple complexities. Intensive Care Med (1999) 0.75
Hyperthermia enhances 17-DMAG efficacy in hepatocellular carcinoma cells with aggravated DNA damage and impaired G2/M transition. Sci Rep (2016) 0.75
Hyperthermia in combined treatment of cancer. Lancet Oncol (2002) 4.41
Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med (1990) 3.93
Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res (1996) 2.86
Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J Exp Med (1989) 2.69
Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med (1989) 2.52
Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res (1996) 2.35
Effects of inhaled nitric oxide on right ventricular function in severe acute respiratory distress syndrome. Intensive Care Med (1995) 2.07
Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique. Int J Hyperthermia (2005) 1.99
Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia (2004) 1.90
High survival rate in 122 ARDS patients managed according to a clinical algorithm including extracorporeal membrane oxygenation. Intensive Care Med (1997) 1.89
Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia. 1993. Int J Hyperthermia (2009) 1.87
Hypoxia modulates the barrier and coagulant function of cultured bovine endothelium. Increased monolayer permeability and induction of procoagulant properties. J Clin Invest (1990) 1.84
Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia. Int J Hyperthermia (1993) 1.77
[Diencephalic pilocytic astrocytoma with clinical onset in infancy. Biological behavior and pathomorphological findings in 11 children]. Zentralbl Allg Pathol (1985) 1.76
Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J Exp Med (1988) 1.71
Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in vivo. Int J Hyperthermia (1998) 1.67
Cellular uptake of magnetic fluid particles and their effects on human adenocarcinoma cells exposed to AC magnetic fields in vitro. Int J Hyperthermia (1997) 1.66
Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome. Anesthesiology (1995) 1.52
Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging? Eur Radiol (2005) 1.49
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia (2010) 1.48
A clinical pilot study of fresh frozen plasma versus human albumin in paediatric craniofacial repair. J Int Med Res (2008) 1.48
Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial. Int J Hyperthermia (2007) 1.48
Bronchial fistulae in ARDS patients: management with an extracorporeal lung assist device. Eur Respir J (2008) 1.42
Simulation studies promote technological development of radiofrequency phased array hyperthermia. 1996. Int J Hyperthermia (2009) 1.41
[Immunonutritive enteral feeding in the critically ill]. Anaesthesist (2002) 1.38
[Diagnostic and therapeutic management of patients receiving antithrombotic drugs: what to heed?]. Dtsch Med Wochenschr (2006) 1.38
Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs (2000) 1.37
Clinical implications of antibiotic-induced endotoxin release in septic shock. Intensive Care Med (2002) 1.34
The prototypic Th2 autoimmunity induced by mercury is dependent on IFN-gamma and not Th1/Th2 imbalance. J Immunol (1998) 1.29
Inhaled nitric oxide: its effects on pulmonary circulation and airway smooth muscle cells. Eur Heart J (1993) 1.28
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia (2012) 1.27
Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients. Ann Oncol (2010) 1.26
Neuropathic gastric dilatation in psittaciformes. Avian Dis (1987) 1.23
Linkage of determinants for streptogramin A, macrolide-lincosamide-streptogramin B, and chloramphenicol resistance on a conjugative plasmid in Enterococcus faecium and dissemination of this cluster among streptogramin-resistant enterococci. Int J Med Microbiol (2000) 1.23
Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol (2010) 1.20
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol (2013) 1.17
Early detection of increased tumour necrosis factor alpha (TNFalpha) and soluble TNF receptor protein plasma levels after trauma reveals associations with the clinical course. Acta Anaesthesiol Scand (2001) 1.16
Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy. Oncology (2003) 1.14
SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Ann Oncol (2014) 1.13
[Radiological evaluation of tumor response in oncological studies (tumor response evaluation)]. Rofo (2011) 1.13
Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: technique and prospective results. Radiology (1995) 1.12
MRI after magnetic drug targeting in patients with advanced solid malignant tumors. Eur Radiol (2004) 1.10
Nitric oxide inhibits tissue factor synthesis, expression and activity in human monocytes by prior formation of peroxynitrite. Intensive Care Med (1998) 1.10
A polypeptide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin. J Biol Chem (1990) 1.09
Radiation risks for the radiologist performing transjugular intrahepatic portosystemic shunt (TIPS). Br J Radiol (2006) 1.08
Comparison of four magnetic resonance methods for mapping small temperature changes. Phys Med Biol (1999) 1.07
Methods and potentials of magnetic resonance imaging for monitoring radiofrequency hyperthermia in a hybrid system. Int J Hyperthermia (2005) 1.06
Establishment and characterization of four cell lines derived from human head and neck squamous cell carcinomas for an autologous tumor-fibroblast in vitro model. Anticancer Res (2000) 1.06
Lupus-prone mice as models to study xenobiotic-induced acceleration of systemic autoimmunity. Environ Health Perspect (1999) 1.05
Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann Hematol (2005) 1.04
Aminoglycoside-streptothricin resistance gene cluster aadE-sat4-aphA-3 disseminated among multiresistant isolates of Enterococcus faecium. Antimicrob Agents Chemother (2001) 1.04
[Recommendations for platelet transfusion by the Joint Thrombocyte Working Party of the German Societies of Transfusion Medicine and Immunohaematology (DGTI), Thrombosis and Haemostasis Research (GTH), and Haematology and Oncology (DGHO)]. Dtsch Med Wochenschr (2006) 1.00
Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia. Eur Respir J (2010) 1.00
Clinical evaluation and verification of the hyperthermia treatment planning system hyperplan. Int J Radiat Oncol Biol Phys (2000) 0.98
Accuracy of endorectal ultrasound after preoperative radiochemotherapy in locally advanced rectal cancer. Surg Endosc (1999) 0.98
Acute basophilic leukemia. Eur J Haematol (2001) 0.97
Blood group determinates incidence for pancreatic cancer in Germany. Front Physiol (2013) 0.96
Comprehensive array CGH of normal karyotype myelodysplastic syndromes reveals hidden recurrent and individual genomic copy number alterations with prognostic relevance. Leukemia (2011) 0.96
Comparison of MR-thermography and planning calculations in phantoms. Med Phys (2006) 0.95
Efficacy of inhaled nitric oxide in patients with severe ARDS. Chest (1995) 0.94
Ventilator-associated pneumonia in trauma patients is associated with lower mortality: results from EU-VAP study. J Trauma (2010) 0.94
[Macrotetrolides]. Fortschr Chem Org Naturst (1968) 0.93
Accuracy of staging rectal tumors with contrast-enhanced transrectal MR imaging. AJR Am J Roentgenol (1997) 0.93
Histologic changes and inclusion bodies in chickens inoculated with an ornithiosis agent. Avian Dis (1968) 0.93
ESHO quality assurance guidelines for regional hyperthermia. Int J Hyperthermia (1998) 0.92
[Nomifensin-induced immune haemolytic anaemias (author's transl)]. Klin Wochenschr (1981) 0.92
Extracorporeal membrane oxygenation for transport of hypoxaemic patients with severe ARDS. Br J Anaesth (1997) 0.92
[Mycobacteria in parrots and parakeets (Psittaciformes)]. Dtsch Tierarztl Wochenschr (1988) 0.91
Anticoagulation: the present and future. Clin Appl Thromb Hemost (2001) 0.91
[Avian mycobacteriosis caused by strains not yet identifiable]. Zentralbl Veterinarmed B (1991) 0.91
The biologic rationale of hyperthermia. Cancer Treat Res (2007) 0.91
High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study. Br J Haematol (2005) 0.90
Simultaneous occurrence of a t(9;22) (Ph) with a t(2;11) in a patient with CML and emergence of a new clone with the t(2;11) alone after imatinib mesylate treatment. Leukemia (2003) 0.90
[Dabigatran therapy--perioperative management and interpretation of coagulation tests]. Hamostaseologie (2012) 0.90
Glioma assessment using quantitative blood volume maps generated by T1-weighted dynamic contrast-enhanced magnetic resonance imaging: a receiver operating characteristic study. Acta Radiol (2006) 0.89
Monosomal karyotype in MDS: explaining the poor prognosis? Leukemia (2013) 0.89
Guidelines for sclerotherapy of varicose veins (ICD 10: I83.0, I83.1, I83.2, and I83.9). Dermatol Surg (2004) 0.88
Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transplant Proc (2002) 0.88
[New macrotetralides from actinomyces]. Helv Chim Acta (1967) 0.88
Current status of radiant whole-body hyperthermia at temperatures >41.5 degrees C and practical guidelines for the treatment of adults. The German 'Interdisciplinary Working Group on Hyperthermia'. Int J Hyperthermia (2005) 0.88
Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial. Hum Gene Ther (2001) 0.88
Pallister-Killian syndrome: normal karyotype in prenatal chorionic villi, in postnatal lymphocytes, and in slowly growing epidermal cells, but mosaic tetrasomy 12p in skin fibroblasts. J Med Genet (1995) 0.88
Preoperative hyperthermia combined with radiochemotherapy in locally advanced rectal cancer: a phase II clinical trial. Ann Surg (1998) 0.88